Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: November 9, 2021
Reporting Period: Third Quarter ended September 30, 2021
Business Context: The filing serves as a notification that the Company issued a press release announcing its financial results for the quarter ended September 30, 2021, and providing a corporate update.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the press release (Exhibit 99.1) containing the financial data but does not explicitly state the numerical values within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only indicates that such results were announced in the attached press release.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that a corporate update was provided alongside the financial results in the press release, but the specific content of this update is not included in the text provided.
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release) for specific revenue, net loss, and cash position figures for Q3 2021.
- Verify the details of the "Corporate Update" mentioned in the press release title for any new clinical trial milestones or strategic shifts.
- Check the Company's most recent 10-Q or 10-K for detailed liquidity and debt covenants, as this 8-K does not contain those tables.
- Confirm the trading status of Common Stock (CAPR) on The Nasdaq Capital Market.